Since MUC1 protein is overexpressed on the surface of multiple types of cancer cells, such a drug delivery system may potentially improve the delivery of anticancer agents to multiple malignancies, such as pancreatic cancer [23], prostate cancer [24], ovarian cancer [25], etc. This evidence concerns the gene MUC1 and ovarian cancer.